Do anti-aging peptides work? What has been tested
Elamipretide, epitalon and MOTS-c: no human trial of any of them against ageing was found, and their lifespan data come from mice, rats and flies.
Peptio Research
On this page7
None of these three peptides sold with ageing claims, elamipretide, epitalon and MOTS-c, has been tested against ageing, lifespan or any ageing outcome in a human trial, in the searches behind this site's pages on them. The closest is a single infusion of elamipretide in 39 older adults, which measured a muscle energy marker and found the effect gone by day 7 1.
The lifespan data are from animals. No lifespan study of elamipretide was found in any species. For MOTS-c, the one mouse lifespan measurement was not significant over the whole survival curve (P = 0.23) 2. For epitalon, mean lifespan did not change in female SHR mice or in rats under standard light 3 4, was 13.5% longer (p<0.05) in one transgenic mouse model whose later reanalysis is described as pointing both ways 5 6, and was reported 11 to 16% longer in fruit flies 7. Every one of these studies comes from one research network, and no independent replication was found.
The only approved product among them is Forzinity, an elamipretide injection, approved in the United States to improve muscle strength in people with Barth syndrome, a rare inherited mitochondrial disease, who weigh at least 30 kg. Its own label says it was not superior to placebo on the primary endpoints of its randomised trial 8. And the human figures that circulate online are mostly not about the product being sold: epitalon's mortality numbers come from a different substance, and MOTS-c's human data are measurements of the peptide the body makes.
What "works" would have to mean
For a peptide to be shown to slow ageing, someone would have to measure ageing: lifespan, or the onset of age-related disease, frailty or death, in a controlled study. None of the work found does that in people. What it measures instead are surrogates, markers that are hoped to track ageing: a rate of energy production in muscle, telomere length in cultured cells, a melatonin breakdown product in urine, blood levels of a peptide. A surrogate moving is not the same as a person ageing more slowly.
In animals, lifespan can be measured, and how it is reported matters. Mean or median lifespan describes the whole group. Maximum lifespan and "the last 10% of survivors" describe only the longest-lived animals in a group.
Elamipretide
Elamipretide, also called SS-31, is the one of the three with published randomised trials of clinical endpoints, all in diseases apart from the single-infusion study in older adults described below. Most of the published ones missed their primary endpoints: in Barth syndrome (12 patients, the randomised phase of TAZPOWER) 9, primary mitochondrial myopathy (218 adults over 24 weeks in MMPOWER-3) 10, heart failure with reduced ejection fraction (71 patients over 4 weeks) 11, heart attack 12, dry age-related macular degeneration with geographic atrophy (176 patients over 48 weeks) 13 and Leber hereditary optic neuropathy, an inherited cause of vision loss (12 patients) 14.
The one published randomised trial in older adults gave 39 people aged 60 to 85, enrolled because their muscle mitochondria were poorly functioning, a single infusion. ATPmax, the maximal rate at which muscle makes ATP, rose borderline immediately afterwards (P = 0.055 for the absolute change, P = 0.045 for the percentage change), was no different by day 7, and fatigue resistance did not change 1.
Epitalon
Epitalon is a synthetic four-amino-acid peptide. No registered human trial of it was found, and no randomised trial measuring a clinical outcome. FDA describes one study of a melatonin breakdown product as randomised and placebo-controlled, while noting it did not specify blinding and measured no sleep outcome 18. The other reports of it being given to people are uncontrolled, come from the group that developed it, and measure surrogates 19 20.
The human mortality figures quoted for epitalon, such as deaths falling 1.6 to 1.8-fold in 266 elderly people, come from studies of epithalamin, an extract of cattle pineal gland. Epithalamin is a mixture; epitalon is one synthetic molecule. Those studies are not evidence about epitalon 22 23.
MOTS-c
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. No result from any human trial of it was found. One placebo-controlled phase 2a trial in 120 adults with prediabetes and overweight or obesity is registered as recruiting, with no results 24.
The human studies that exist measure the MOTS-c the body makes, and find associations in conflicting directions: a 2024 meta-analysis of 602 people found plasma levels lower in type 2 diabetes but higher in obesity, the obesity result significant only after overweight participants were excluded 25. The blood test itself is in doubt. A mass spectrometry method could not confirm the ELISA-measured levels in 20 healthy people 26, and a 2024 correction by other researchers states that endogenous MOTS-c "still remains undetected" by that method 27.
The only human data on an administered peptide concern CB4211, a different molecule. In a press release filed with the SEC on 10 August 2021, its developer, CohBar, called it "a novel and improved analog of MOTS-c" and reported topline results; that is the company's own, unreviewed announcement 28. The trial's registry record lists it as completed in April 2021 with no results posted, and no peer-reviewed publication was found 29.
What the surrogates are
Each of the three has a marker that stands in for an outcome nobody has measured:
- Elamipretide: ATPmax in muscle, measured immediately after one infusion in older adults 1.
- Epitalon: telomere length and telomerase activity in cultured human cells, not in people 30. In white blood cells from 11 donors, telomeres lengthened in 5 and shortened in 2 31. In an independent 2025 study, telomeres also lengthened in breast cancer cell lines 32. In people, the marker is a melatonin breakdown product in urine, 1.7 times higher in a report with no stated sample size or control group 19.
- MOTS-c: plasma levels of the body's own peptide, measured by an assay mass spectrometry has not confirmed 26.
No study measuring telomere length in people given epitalon was found, and no published human study testing whether taking MOTS-c does anything was found.
What regulators say
The three sit in different places with FDA. Elamipretide is approved as Forzinity, on 19 September 2025, under accelerated approval to improve muscle strength in Barth syndrome patients weighing at least 30 kg, an approval based on what the label calls an intermediate clinical endpoint, with continued approval possibly contingent on a confirmatory trial 33 8. That approval covers the approved product for that indication, and says nothing about material sold under the same name.
Epitalon and MOTs-C, FDA's spelling, appear on FDA's compounding pages, both in its table of bulk drug substances nominated for compounding but withdrawn 34. Both were nonetheless on the agenda of FDA's Pharmacy Compounding Advisory Committee in July 2026: MOTs-C on 23 July for obesity and osteoporosis, epitalon on 24 July for insomnia. No outcome was found on the meeting page, reopened on 6 November 2026 35. A trade journal and a law firm, both second hand, report that the committee voted to recommend both for the list, MOTS-c by 7 to 5 with two abstentions in the journal's account 36 37. That is advice on compounding, against FDA's own briefings, and says nothing about ageing 36. In October 2026 HHS said it does not intend to act against compounders of epitalon acetate or MOTS-c acetate who meet ten listed conditions 38. That is a draft, non-binding enforcement position 39, not an approval, and it says nothing about ageing either.
Peptides covered
Research areas
Sources
- 1. Roshanravan B et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021. PubMed 34264994(open access)
- 2. Reynolds JC, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. PubMed 33473109(open access)
- 3. Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003. PubMed 14501183
- 4. Vinogradova IA et al. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bulletin of Experimental Biology and Medicine. 2007. PubMed 18856211
- 5. Anisimov VN et al. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. Bulletin of Experimental Biology and Medicine. 2002. PubMed 12459848
- 6. Araj SK et al. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. 2025. PubMed 40141333(open access)
- 7. Khavinson VK et al. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development. 2000. PubMed 11087911
- 8. FORZINITY (elamipretide) injection, prescribing information (Revised 9/2025). DailyMed, U.S. National Library of Medicine (FDA-approved labeling). 2025. View source(open access)
- 9. Reid Thompson W et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine. 2021. PubMed 33077895
- 10. Karaa A et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023. PubMed 37268435
- 11. Butler J et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. Journal of Cardiac Failure. 2020. PubMed 32068002
- 12. Gibson CM et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal. 2016. PubMed 26586786
- 13. Ehlers JP et al. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmology Science. 2025. PubMed 39605874(open access)
- 14. Karanjia R, Sadun AA. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial. Ophthalmology. 2024. PubMed 37923251
- 15. Mitchell W et al. The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell. 2025. PubMed 40080911(open access)
- 16. Campbell MD, Samuelson AT, Chiao YA. Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice. GeroScience. 2023. PubMed 36840897
- 17. Chiao YA, Zhang H, Sweetwyne M. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife. 2020. PubMed 32648542(open access)
- 18. FDA Briefing Document for Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate), Pharmacy Compounding Advisory Committee, July 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 19. Ivko OM et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Advances in Gerontology (Uspekhi Gerontologii). 2020. PubMed 33280326
- 20. Khavinson V et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters. 2002. PubMed 12195242
- 21. Vinogradova IA et al. Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens. Bulletin of Experimental Biology and Medicine. 2008. PubMed 19110597
- 22. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. 2003. PubMed 14523363
- 23. Korkushko OV et al. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bulletin of Experimental Biology and Medicine. 2006. PubMed 17426848
- 24. A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c. ClinicalTrials.gov. 2026. NCT07505745(open access)
- 25. Zhou Q et al. The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. 2024. PubMed 39160573(open access)
- 26. Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry. 2019. PubMed 30394592
- 27. Emser SV et al. Corrigendum: Extension of mitogenome enrichment based on single long-range PCR: mtDNAs and putative mitochondrial-derived peptides of five rodent hibernators. Frontiers in Genetics. 2024. View source(open access)
- 28. CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity (Form 8-K Exhibit 99.2). CohBar, Inc., filed with the U.S. Securities and Exchange Commission. 2021. View source(open access)
- 29. A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. ClinicalTrials.gov. 2021. NCT03998514(open access)
- 30. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003. PubMed 12937682
- 31. Khavinson VK et al. Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes. Bulletin of Experimental Biology and Medicine. 2019. PubMed 31761987
- 32. Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. PubMed 40908429(open access)
- 33. Drugs@FDA: FORZINITY (elamipretide hydrochloride), NDA 215244. U.S. Food and Drug Administration. 2025. View source(open access)
- 34. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
- 35. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026. View source(open access)
- 36. Steinzor P. FDA Panel Backs 6 Peptides for Compounding. AJMC (The American Journal of Managed Care). 2026. View source(open access)
- 37. Crossan SS, Watkins S. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight Alert. 2026. View source(open access)
- 38. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. U.S. Department of Health and Human Services. 2026. View source(open access)
- 39. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526). Federal Register. 2026. View source(open access)